PFE Pfizer

XNYS Up Alert

Health Care

· How we analyze

About the company

Pfizer is a major US pharmaceutical company. It develops and sells prescription drugs and vaccines, for example for cancer, infections and cardiovascular disease. Most recently it became known for the coronavirus vaccine developed together with Biontech. Pfizer operates worldwide. As of Oct 11, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · New York, USA

According to the company, the group researches, develops, manufactures and markets biopharmaceutical products worldwide, and Biopharma is the only reportable segment. In November 2025 the group acquired Metsera. Research focuses on oncology, internal medicine including cardiovascular, metabolism, weight management and migraine, vaccines, and inflammation and immunology. Its products include Eliquis, the Prevnar vaccine family, the Comirnaty vaccine and Paxlovid for COVID. Prescription drugs go mainly to wholesalers and also directly to retailers, hospitals, government agencies and pharmacies. In the US market, vaccines go mainly to the federal government, wholesalers, physician offices, pharmacies and integrated delivery systems.

Automatically summarized from SEC annual report (10-K, filed Feb 26, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today +0.0%
  • 7 days −1.0%
  • 30 days +3.9%
  • 1 year +20.3%
Day range (last trading day)
−1.0%Price at 83% of the range+0.2%
52-week range
−20.7%Price at 91% of the range+2.1%
Distance from the all-time high
−51.7%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Double bottom · Analysis method

Pattern detected

Pattern detected on Oct 14, 2026. The pattern applies for at most 15 trading days.

What does the pattern show?

What is this? The price has formed two similarly deep lows and broken above the neckline between them. This is seen as a sign that the downward move is ending.

This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:PFE

Fundamental analysis

Pfizer · Sector Health Care · amounts in USD

Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 26, 2026.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality Profitability, consistency, balance sheet · 1 without data 6 of 7 criteria met Growth Revenue and earnings per share · 1 without data 1 of 6 criteria met Dividend Level, consistency, coverage 5 of 7 criteria met Financial strength Piotroski, debt, liquidity 5 of 6 criteria met

Quality 6 of 7 met · 1 without data

  • met: Gross margin above 40% 74.3%
  • no data: Operating margin above 15% not stated in the SEC filings
  • met: Net margin above 10% 12.4%
  • not met: Return on equity above 15% 9.0%
  • met: Free cash flow margin above 10% 14.5%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 41.5%
Gross margin

74.3% Fiscal year 2025

Rank 85 of 100: higher than 85% of 153 peers (All). strong.

Rank 73 of 100: higher than 73% of 20 peers (Sector). strong.

Median Health Care: 66.6%

Share of revenue left after the direct cost of the products sold.

Net margin

12.4% Fiscal year 2025

Rank 44 of 100: higher than 44% of 237 peers (All). medium.

Rank 40 of 100: higher than 40% of 26 peers (Sector). medium.

Median Health Care: 13.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

9.0% Fiscal year 2025

Rank 27 of 100: higher than 27% of 218 peers (All). weak.

Rank 21 of 100: higher than 21% of 21 peers (Sector). weak.

Median Health Care: 14.3%

Net income divided by equity at fiscal year end.

Return on assets

3.7% Fiscal year 2025 (total assets at year end)

Rank 33 of 100: higher than 33% of 238 peers (All). medium.

Rank 21 of 100: higher than 21% of 26 peers (Sector). weak.

Median Health Care: 6.4%

Net income divided by total assets at fiscal year end.

Equity ratio

41.5% Fiscal year 2025

Rank 60 of 100: higher than 60% of 239 peers (All). medium.

Rank 60 of 100: higher than 60% of 26 peers (Sector). medium.

Median Health Care: 38.5%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

14.5% Fiscal year 2025

Rank 50 of 100: higher than 50% of 213 peers (All). medium.

Rank 46 of 100: higher than 46% of 25 peers (Sector). medium.

Median Health Care: 14.9%

Free cash flow divided by revenue.

Free cash flow

9.1B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 1 of 6 met · 1 without data

  • not met: Over 3 years, revenue grew by more than 5% per year −14.6%
  • met: Over 5 years, revenue grew by more than 5% per year +8.5%
  • no data: Over 10 years, revenue grew by more than 5% per year no comparable figures over 10 years
  • not met: Over 3 years, EPS grew by more than 5% per year −37.1%
  • not met: Over 5 years, EPS grew by more than 5% per year −4.5%
  • not met: Revenue rose in at least 4 of the last 5 fiscal years 3 of 5
  • not met: Revenue rose in the last fiscal year −1.6%
Revenue growth 3 years

−14.6% per year

Rank 3 of 100: higher than 3% of 230 peers (All). weak.

Rank 10 of 100: higher than 10% of 25 peers (Sector). weak.

Median Health Care: +5.6%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+8.5% per year

Rank 37 of 100: higher than 37% of 217 peers (All). medium.

Rank 50 of 100: higher than 50% of 25 peers (Sector). medium.

Median Health Care: +8.5%

Average growth per year over 5 fiscal years.

EPS growth 3 years

−37.1% per year

Rank 2 of 100: higher than 2% of 157 peers (All). weak.

Rank 2 of 100: higher than 2% of 22 peers (Sector). weak.

Median Health Care: +5.5%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

−4.5% per year

Rank 7 of 100: higher than 7% of 146 peers (All). weak.

Rank 8 of 100: higher than 8% of 20 peers (Sector). weak.

Median Health Care: +7.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+2.1% per year

Rank 15 of 100: higher than 15% of 140 peers (All). weak.

Rank 23 of 100: higher than 23% of 20 peers (Sector). weak.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 5 of 7 met

  • met: Pays a dividend 1.72 USD
  • not met: Payout ratio at most 60% of earnings 126%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +2.4%
  • not met: Free cash flow per share covers the dividend 0.9x
  • met: Dividends paid over the last 5 years covered by free cash flow 58% of free cash flow
Payout ratio

126% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+2.4% per year

Rank 10 of 100: higher than 10% of 118 peers (All). weak.

Rank 3 of 100: higher than 3% of 16 peers (Sector). weak.

Median Health Care: +7.8%

Growth of the dividend per share per year.

Free cash flow coverage

0.9x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 5 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 6 of 9
  • met: Long-term debt no higher than equity 0.71
  • met: Current assets cover current liabilities 1.16
  • met: Positive equity 86.5B USD
  • met: In 5 years, share count up by at most 5% +1.4%
  • met: Free cash flow positive in the last fiscal year 9.1B USD
Piotroski F-Score

6 of 9 Fiscal year 2025

Rank 45 of 100: higher than 45% of 134 peers (All). medium.

Rank 32 of 100: higher than 32% of 19 peers (Sector). weak.

Median Health Care: 7.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.71 at fiscal year end

Rank 45 of 100: lower than 45% of 199 peers (All). medium.

Rank 53 of 100: lower than 53% of 18 peers (Sector). medium.

Median Health Care: 0.72

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.16 at fiscal year end

Rank 37 of 100: higher than 37% of 215 peers (All). medium.

Rank 33 of 100: higher than 33% of 26 peers (Sector). medium.

Median Health Care: 1.56

Current assets divided by current liabilities.

Change in share count

+1.4% in 5 years

Rank 38 of 100: lower than 38% of 199 peers (All). medium.

Rank 19 of 100: lower than 19% of 24 peers (Sector). weak.

Median Health Care: −2.7%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • not met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light green: Revenue grew over 5 years (+8.5% per year), at least as fast as the sector median.
  • Light red: Net income (total) shrank over 5 years (−4.2% per year); per share −4.5% per year.
  • Light yellow: Net margin 12.4%, below the sector median (12.9%).
  • Light yellow: Debt higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.
  • Light red: Dividend higher than earnings.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 52.8B USD · Net income 7.2B USD · Net margin 13.7%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 52.5B USD · Net income 21.3B USD · Net margin 40.6%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 53.6B USD · Net income 11.2B USD · Net margin 20.8%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 51.8B USD · Net income 16.3B USD · Net margin 31.4%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 41.7B USD · Net income 9.6B USD · Net margin 23.1%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 81.3B USD · Net income 22.0B USD · Net margin 27.0%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 100.3B USD · Net income 31.4B USD · Net margin 31.3%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 58.5B USD · Net income 2.1B USD · Net margin 3.6%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 63.6B USD · Net income 8.0B USD · Net margin 12.6%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 62.6B USD · Net income 7.8B USD · Net margin 12.4%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 62.6B USD · Net income 7.8B USD · Net margin 12.4%

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 74.3 USD gross profit and 12.4 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue62.6B USD100.0%
Gross profit46.5B USD74.3%
Cost of revenue16.1B USD25.7%
Net income7.8B USD12.4%
Research & development10.4B USD16.7%
Interest expense2.7B USD4.3%
Remaining costs, taxes & other25.6B USD41.0%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The net margin fell in 5 years from 23.1% to 12.4%.

Gross marginNet margin
  1. Fiscal year 2016: Gross margin 76.7% · Net margin 13.7%
  2. Fiscal year 2017: Gross margin 78.6% · Net margin 40.6%
  3. Fiscal year 2018: Gross margin 79.0% · Net margin 20.8%
  4. Fiscal year 2019: Gross margin 80.3% · Net margin 31.4%
  5. Fiscal year 2020: Gross margin 79.1% · Net margin 23.1%
  6. Fiscal year 2021: Gross margin 62.1% · Net margin 27.0%
  7. Fiscal year 2022: Gross margin 65.8% · Net margin 31.3%
  8. Fiscal year 2023: Gross margin 57.3% · Net margin 3.6%
  9. Fiscal year 2024: Gross margin 71.9% · Net margin 12.6%
  10. Fiscal year 2025: Gross margin 74.3% · Net margin 12.4%

Returns

Return on equity fell in 5 years from 15.2% to 9.0%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 12.1% · Return on assets 4.2%
  2. Fiscal year 2017: Return on equity 29.9% · Return on assets 12.4%
  3. Fiscal year 2018: Return on equity 17.6% · Return on assets 7.0%
  4. Fiscal year 2019: Return on equity 25.8% · Return on assets 9.7%
  5. Fiscal year 2020: Return on equity 15.2% · Return on assets 6.2%
  6. Fiscal year 2021: Return on equity 28.5% · Return on assets 12.1%
  7. Fiscal year 2022: Return on equity 32.8% · Return on assets 15.9%
  8. Fiscal year 2023: Return on equity 2.4% · Return on assets 0.9%
  9. Fiscal year 2024: Return on equity 9.1% · Return on assets 3.8%
  10. Fiscal year 2025: Return on equity 9.0% · Return on assets 3.7%

Equity and long-term debt

The equity ratio stayed roughly the same in 5 years (41.5%).

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 59.5B USD · Long-term debt 31.4B USD
  2. Fiscal year 2017: Equity 71.3B USD · Long-term debt 33.5B USD
  3. Fiscal year 2018: Equity 63.4B USD · Long-term debt 32.9B USD
  4. Fiscal year 2019: Equity 63.1B USD · Long-term debt 36.0B USD
  5. Fiscal year 2020: Equity 63.2B USD · Long-term debt 37.1B USD
  6. Fiscal year 2021: Equity 77.2B USD · Long-term debt 36.2B USD
  7. Fiscal year 2022: Equity 95.7B USD · Long-term debt 32.9B USD
  8. Fiscal year 2023: Equity 89.0B USD · Long-term debt 61.5B USD
  9. Fiscal year 2024: Equity 88.2B USD · Long-term debt 57.4B USD
  10. Fiscal year 2025: Equity 86.5B USD · Long-term debt 61.6B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 1.35 to 1.16.

Current ratio
  1. Fiscal year 2016: Current ratio 1.25
  2. Fiscal year 2017: Current ratio 1.35
  3. Fiscal year 2018: Current ratio 1.57
  4. Fiscal year 2019: Current ratio 0.88
  5. Fiscal year 2020: Current ratio 1.35
  6. Fiscal year 2021: Current ratio 1.40
  7. Fiscal year 2022: Current ratio 1.22
  8. Fiscal year 2023: Current ratio 0.91
  9. Fiscal year 2024: Current ratio 1.17
  10. Fiscal year 2025: Current ratio 1.16

Cash flow

Free cash flow fell in 5 years from 12.2B USD to 9.1B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 15.9B USD · Capital expenditure 1.8B USD · Free cash flow 14.1B USD
  2. Fiscal year 2017: Operating cash flow 16.5B USD · Capital expenditure 2.0B USD · Free cash flow 14.5B USD
  3. Fiscal year 2018: Operating cash flow 15.8B USD · Capital expenditure 2.0B USD · Free cash flow 13.8B USD
  4. Fiscal year 2019: Operating cash flow 12.6B USD · Capital expenditure 2.2B USD · Free cash flow 10.4B USD
  5. Fiscal year 2020: Operating cash flow 14.4B USD · Capital expenditure 2.3B USD · Free cash flow 12.2B USD
  6. Fiscal year 2021: Operating cash flow 32.6B USD · Capital expenditure 2.7B USD · Free cash flow 29.9B USD
  7. Fiscal year 2022: Operating cash flow 29.3B USD · Capital expenditure 3.2B USD · Free cash flow 26.0B USD
  8. Fiscal year 2023: Operating cash flow 8.7B USD · Capital expenditure 3.9B USD · Free cash flow 4.8B USD
  9. Fiscal year 2024: Operating cash flow 12.7B USD · Capital expenditure 2.9B USD · Free cash flow 9.8B USD
  10. Fiscal year 2025: Operating cash flow 11.7B USD · Capital expenditure 2.6B USD · Free cash flow 9.1B USD

Share count

The share count rose in 5 years by 1.4% – more new shares were issued than repurchased (dilution).

Diluted share count
  1. Fiscal year 2016: Diluted share count 6.2B
  2. Fiscal year 2017: Diluted share count 6.1B
  3. Fiscal year 2018: Diluted share count 6.0B
  4. Fiscal year 2019: Diluted share count 5.7B
  5. Fiscal year 2020: Diluted share count 5.6B
  6. Fiscal year 2021: Diluted share count 5.7B
  7. Fiscal year 2022: Diluted share count 5.7B
  8. Fiscal year 2023: Diluted share count 5.7B
  9. Fiscal year 2024: Diluted share count 5.7B
  10. Fiscal year 2025: Diluted share count 5.7B

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
1.72 USD · Fiscal year 2025
Dividend growth per year
3 y +2.2%5 y +2.4%10 y +4.4%
Years without a cut
at least 10 as far as the data goes
Payout ratio
of earnings 126% of free cash flow 108%
To shareholders (5 years)
48.5B USD 4% through repurchases
Share count over 5 years
+1.4% more shares – dilution

Dividend per share

The dividend per share rose in 5 years from 1.53 USD to 1.72 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 1.22 USD
  2. Fiscal year 2017: Dividend per share 1.30 USD
  3. Fiscal year 2018: Dividend per share 1.38 USD
  4. Fiscal year 2019: Dividend per share 1.46 USD
  5. Fiscal year 2020: Dividend per share 1.53 USD
  6. Fiscal year 2021: Dividend per share 1.57 USD
  7. Fiscal year 2022: Dividend per share 1.61 USD
  8. Fiscal year 2023: Dividend per share 1.65 USD
  9. Fiscal year 2024: Dividend per share 1.69 USD
  10. Fiscal year 2025: Dividend per share 1.72 USD

Payout ratios

The payout ratio rose in 5 years from 89.5% to 126.5%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2016: Payout ratio (earnings) 104.3% · Payout ratio (free cash flow) 52.9%
  2. Fiscal year 2017: Payout ratio (earnings) 36.9% · Payout ratio (free cash flow) 53.7%
  3. Fiscal year 2018: Payout ratio (earnings) 73.8% · Payout ratio (free cash flow) 58.5%
  4. Fiscal year 2019: Payout ratio (earnings) 50.9% · Payout ratio (free cash flow) 78.5%
  5. Fiscal year 2020: Payout ratio (earnings) 89.5% · Payout ratio (free cash flow) 70.5%
  6. Fiscal year 2021: Payout ratio (earnings) 40.8% · Payout ratio (free cash flow) 29.5%
  7. Fiscal year 2022: Payout ratio (earnings) 29.4% · Payout ratio (free cash flow) 34.7%
  8. Fiscal year 2023: Payout ratio (earnings) 445.9% · Payout ratio (free cash flow) 194.4%
  9. Fiscal year 2024: Payout ratio (earnings) 119.9% · Payout ratio (free cash flow) 97.4%
  10. Fiscal year 2025: Payout ratio (earnings) 126.5% · Payout ratio (free cash flow) 107.8%

What goes back to shareholders

Over 5 years, 48.5B USD went back to shareholders, 4% of it through share repurchases. That is 61% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD Dividends partly reported as declared rather than paid.
  1. Fiscal year 2016: Dividends paid 7.4B USD · Share repurchases 5.0B USD · New shares issued (including employee plans) not available · Free cash flow 14.1B USD
  2. Fiscal year 2017: Dividends paid 7.8B USD · Share repurchases 5.0B USD · New shares issued (including employee plans) not available · Free cash flow 14.5B USD
  3. Fiscal year 2018: Dividends paid 8.1B USD · Share repurchases 12.2B USD · New shares issued (including employee plans) not available · Free cash flow 13.8B USD
  4. Fiscal year 2019: Dividends paid 8.2B USD · Share repurchases 8.9B USD · New shares issued (including employee plans) not available · Free cash flow 10.4B USD
  5. Fiscal year 2020: Dividends paid 8.6B USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 12.2B USD
  6. Fiscal year 2021: Dividends paid 8.8B USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 29.9B USD
  7. Fiscal year 2022: Dividends paid 9.0B USD · Share repurchases 2.0B USD · New shares issued (including employee plans) not available · Free cash flow 26.0B USD
  8. Fiscal year 2023: Dividends paid 9.3B USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 4.8B USD
  9. Fiscal year 2024: Dividends paid 9.6B USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 9.8B USD
  10. Fiscal year 2025: Dividends paid 9.8B USD · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 9.1B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Pfizer next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison PFE, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
JNJ Johnson & Johnson 94.2B USD +2.7%67.9%–28.5%32.9%40.9%20.9%4/9
HCA HCA Healthcare 75.6B USD +8.0%––9.0%–−9.9%10.2%–
LLY Lilly (Eli) 65.2B USD +21.6%83.0%–31.7%77.8%23.6%13.8%7/9
MRK Merck & Co. 65.0B USD +6.3%74.8%–28.1%34.7%38.4%19.0%4/9
PFE Pfizer this stock 62.6B USD +8.5%74.3%–12.4%9.0%41.5%14.5%6/9
ABBV AbbVie 61.2B USD +6.0%70.2%24.6%6.9%–−2.4%29.1%8/9
BMY Bristol Myers Squibb 48.2B USD +2.5%71.1%–14.6%38.2%20.5%26.7%8/9
TMO Thermo Fisher Scientific 44.6B USD +6.7%–17.4%15.0%12.6%48.4%14.1%–
ABT Abbott Laboratories 44.3B USD +5.1%56.4%18.2%14.7%12.5%60.1%16.7%6/9
Median of the sector 26 symbols 44.4B USD +8.5%66.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+8.5% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 8.5% per year on average – at least as fast as the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light red: shrinking

−4.2% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: −4.5% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it fell by 4.2% per year on average. The median company in the sector reached +7.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

12.4% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 12.42 USD remained as profit – less than the median company in the sector (12.9%). Five years ago the margin was 23.1%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light yellow: higher than sector

0.71 latest balance sheet

Sector Health Care: median 0.66 (49 symbols)

What does this mean? For every 1 USD of equity there is 0.71 USD of financial debt – more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light red: above earnings

126% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? The payout was higher than the earnings per share; it is paid from cash flow, from reserves or with new debt. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
62.6B USD
Revenue vs. prior year
−1.6%
Net income (FY)
7.8B USD
Net income vs. prior year
−3.2%
EPS (FY)
1.36 USD
13F funds with a position
1 of 9
Funds vs. prior quarter
±0
Shares held vs. prior quarter
−84.0%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 26, 2026 · Balance sheet Jun 28, 2026 (filed Aug 4, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 62.6B7.8B 12.4% 1.36 1.72 126%
2024Dec 31, 2024 63.6B8.0B 12.6% 1.41 1.69 120%
2023Dec 31, 2023 58.5B2.1B 3.6% 0.37 1.65 446%
2022Dec 31, 2022 100.3B31.4B 31.3% 5.47 1.61 29%
2021Dec 31, 2021 81.3B22.0B 27.0% 3.85 1.57 41%
2020Dec 31, 2020 41.7B9.6B 23.1% 1.71 1.53 89%
2019Dec 31, 2019 51.8B16.3B 31.4% 2.87 1.46 51%
2018Dec 31, 2018 53.6B11.2B 20.8% 1.87 1.38 74%
2017Dec 31, 2017 52.5B21.3B 40.6% 3.52 1.30 37%
2016Dec 31, 2016 52.8B7.2B 13.7% 1.17 1.22 104%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 28, 2026 15.0B−248.0M −1.6% −0.04 0.86 –
Q1/26Mar 29, 2026 14.5B2.7B 18.6% 0.47 0.00 0%
Q4/25*Dec 31, 2025 17.6B−1.6B −9.4% – 0.86 –
Q3/25Sep 28, 2025 16.7B3.5B 21.3% 0.62 0.00 0%
Q2/25Jun 29, 2025 14.7B2.9B 19.9% 0.51 0.86 169%
Q1/25Mar 30, 2025 13.7B3.0B 21.6% 0.52 0.00 0%
Q4/24*Dec 31, 2024 17.8B410.0M 2.3% – 0.85 –
Q3/24Sep 29, 2024 17.7B4.5B 25.2% 0.78 0.00 0%
Q2/24Jun 30, 2024 13.3B41.0M 0.3% 0.01 0.84 8,400%
Q1/24Mar 31, 2024 14.9B3.1B 20.9% 0.55 0.00 0%
Q4/23*Dec 31, 2023 14.2B−3.4B −23.6% – 0.83 –
Q3/23Oct 1, 2023 13.2B−2.4B −18.0% −0.42 0.00 –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $3.0M3 people $83.3K1 person +$2.9M
6 months $3.0M3 people $134.7K1 person +$2.8M
12 months $3.0M3 people $134.7K1 person +$2.8M

Latest transactions

  • Aug 12, 2026 Bourla Albert Chief executive (CEO), Director Open-market purchase 38,000 shares · $1.0M · SEC
  • Aug 5, 2026 Damico Jennifer B. Officer Open-market sale 3,278 shares · $83.3K · SEC
  • Aug 5, 2026 Blaylock Ronald E Director Open-market purchase 39,231 shares · $998.8K · SEC
  • Aug 5, 2026 Buckley Mortimer J Director Open-market purchase 37,632 shares · $960.4K · SEC
  • Jun 9, 2026 Damico Jennifer B. Officer Open-market sale 2,000 shares · $51.4K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +80

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+0
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)29.0
Rel. strength 60 d+17.9%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on PFE yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: PFE

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close